TY - JOUR
T1 - Toxoplasmosis in transplant recipients, Europe, 2010–2014
AU - Robert-Gangneux, Florence
AU - Meroni, Valeria
AU - Dupont, Damien
AU - Botterel, Françoise
AU - Aguado Garcia, José M.
AU - Brenier-Pinchart, Marie Pierre
AU - Accoceberry, Isabelle
AU - Akan, Hamdi
AU - Abbate, Isabella
AU - Boggian, Katia
AU - Bruschi, Fabrizio
AU - Carratalà, Jordi
AU - David, Miruna
AU - Drgona, Lubos
AU - Djurković-Djaković, Olgica
AU - Farinas, Maria Carmen
AU - Genco, Francesca
AU - Gkrania-Klotsas, Effrossyni
AU - Groll, Andreas H.
AU - Guy, Edward
AU - Hirzel, Cédric
AU - Khanna, Nina
AU - Kurt, Özgür
AU - Junie, Lia Monica
AU - Lazzarotto, Tiziana
AU - Len, Oscar
AU - Mueller, Nicolas J.
AU - Munoz, Patricia
AU - Pana, Zoi Dorothea
AU - Roilides, Emmanuel
AU - Stajner, Tijana
AU - Van Delden, Christian
AU - Villena, Isabelle
AU - Pelloux, Hervé
AU - Manuel, Oriol
N1 - Publisher Copyright:
© 2018, Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2018/8
Y1 - 2018/8
N2 - Transplantation activity is increasing, leading to a growing number of patients at risk for toxoplasmosis. We reviewed toxoplasmosis prevention practices, prevalence, and outcomes for hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT; heart, kidney, or liver) patients in Europe. We collected electronic data on the transplant population and prevention guidelines/regulations and clinical data on toxoplasmosis cases diagnosed during 2010–2014. Serologic pretransplant screening of allo-hematopoietic stem cell donors was performed in 80% of countries, screening of organ donors in 100%. SOT recipients were systematically screened in 6 countries. Targeted anti-Toxoplasma chemoprophylaxis was heterogeneous. A total of 87 toxoplasmosis cases were recorded (58 allo-HSCTs, 29 SOTs). The 6-month survival rate was lower among Toxoplasma-seropositive recipients and among allo-hematopoietic stem cell and liver recipients. Chemoprophylaxis improved outcomes for SOT recipients. Toxoplasmosis remains associated with high mortality rates among transplant recipients. Guidelines are urgently needed to standardize prophylactic regimens and optimize patient management.
AB - Transplantation activity is increasing, leading to a growing number of patients at risk for toxoplasmosis. We reviewed toxoplasmosis prevention practices, prevalence, and outcomes for hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT; heart, kidney, or liver) patients in Europe. We collected electronic data on the transplant population and prevention guidelines/regulations and clinical data on toxoplasmosis cases diagnosed during 2010–2014. Serologic pretransplant screening of allo-hematopoietic stem cell donors was performed in 80% of countries, screening of organ donors in 100%. SOT recipients were systematically screened in 6 countries. Targeted anti-Toxoplasma chemoprophylaxis was heterogeneous. A total of 87 toxoplasmosis cases were recorded (58 allo-HSCTs, 29 SOTs). The 6-month survival rate was lower among Toxoplasma-seropositive recipients and among allo-hematopoietic stem cell and liver recipients. Chemoprophylaxis improved outcomes for SOT recipients. Toxoplasmosis remains associated with high mortality rates among transplant recipients. Guidelines are urgently needed to standardize prophylactic regimens and optimize patient management.
UR - https://www.scopus.com/pages/publications/85050396812
U2 - 10.3201/eid2408.180045
DO - 10.3201/eid2408.180045
M3 - Article
C2 - 30014843
AN - SCOPUS:85050396812
SN - 1080-6040
VL - 24
SP - 1497
EP - 1504
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 8
ER -
SDG 3 Good Health and Well-being